LPL and B-cell chronic lymphocytic leukemia: Among the three disease categories, patients with CLL or WM/LPL had significantly longer periods of BTKi use (45.7 and 36.0 months, respectively) compared to the patients with MCL (16.0 months) (P<0.001, Figure 4A).